Patents by Inventor Drew Dudgeon

Drew Dudgeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF
    Publication number: 20240158515
    Abstract: The present invention provides antibodies that bind specifically to FGFR3 and methods for treating or preventing cancer, such as bladder cancer.
    Type: Application
    Filed: November 14, 2023
    Publication date: May 16, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yan YANG, Christopher DALY, William OLSON, Tammy T. HUANG, Drew DUDGEON, Robert BABB
  • ANTI-GITR ANTIBODIES AND USES THEREOF
    Publication number: 20240076396
    Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 7, 2024
    Inventors: Robert Babb, Drew Dudgeon, Yu Huang, Rosalynn Molden, William Olson, Matthew Sleeman, Dimitris Skokos, Bei Wang
  • Anti-GITR antibodies and uses thereof
    Patent number: 11787867
    Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 17, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert Babb, Drew Dudgeon, Yu Huang, Rosalynn Molden, William Olson, Matthew Sleeman, Dimitris Skokos, Bei Wang
  • Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules That Bind PSMA and CD3, and Uses Thereof
    Publication number: 20210403595
    Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.
    Type: Application
    Filed: September 16, 2021
    Publication date: December 30, 2021
    Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique
  • ANTI-GITR ANTIBODIES AND USES THEREOF
    Publication number: 20210340267
    Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.
    Type: Application
    Filed: March 5, 2021
    Publication date: November 4, 2021
    Inventors: Robert Babb, Drew Dudgeon, Yu Huang, Rosalynn Molden, William Olson, Matthew Sleeman, Dimitris Skokos, Bei Wang
  • Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
    Patent number: 11155633
    Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: October 26, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique
  • Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof
    Publication number: 20190127480
    Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.
    Type: Application
    Filed: November 30, 2018
    Publication date: May 2, 2019
    Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Harber, Drew Dudgeon, Ashique Rafique
  • Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
    Patent number: 10179819
    Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: January 15, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique